Windtree Therapeutics, a Nasdaq-listed biotech firm, has announced a plan to purchase up to $700 million in BNB, the digital currency linked to Binance, following its recent all-time high price. The company aims to bolster its balance sheet by acquiring BNB with a mixture of funding sources, including a $500 million equity line of credit and an additional $20 million agreement. This strategic move also follows the example set by companies like Strategy (formerly MicroStrategy), which have invested heavily in cryptocurrencies to enhance their stock valuations. Windtree’s CEO, Jed Latkin, emphasized the necessity of securing funds to continue acquiring BNB, highlighting the growing trend of publicly traded firms building crypto assets into their financial strategies. Currently, BNB ranks as the fifth-largest cryptocurrency, boasting a market cap of $106.9 billion. Windtree's shares have seen a significant uptick, rising 162% over the past month despite a recent dip of about 5%.

Source 🔗